N/A
Completed N=31
Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
Source: ClinicalTrials.gov NCT00200850 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
Summary
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances. Specifically, this study will determine the effectiveness of SLIT at two different dosing regimens for patients with intermittent mild asthma caused by dust mites.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment |
75.0; 69.5; 141.4; 74.8; 100.9; 83.3 | — |
Eligibility Criteria
Inclusion Criteria
- House dust mite-induced allergic rhinitis/mild intermittent asthma
Exclusion Criteria
- Use of previous allergy immunotherapy for house dust mite asthma
- Pregnancy or breastfeeding
Data sourced from ClinicalTrials.gov (NCT00200850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.